People generally assume that medicines approved for public use are monitored closely by authorities.
A key part of that system is the reporting of possible side effects once treatments reach patients. When those reporting systems are questioned, regulators tend to react quickly.
That is now the case for Danish pharmaceutical company Novo Nordisk, which has received a formal warning from the United States drug regulator.
Regulators step in
The U.S. Food and Drug Administration (FDA) has sent a warning letter to Novo Nordisk regarding how the company reported potential adverse reactions linked to some of its medicines.
Also read: Experts explain why hair loss occurs – and what you can do about it
According to reporting by CBS News, the issue was identified during an inspection of Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey.
The inspection took place in early 2025 and focused on whether the company followed required procedures for submitting safety information.
The warning letter was issued on March 5 and addresses whether the pharmaceutical company complied with established reporting protocols.
Focus on semaglutide
The FDA’s review references several serious cases involving treatments that contain semaglutide, an active ingredient used in widely prescribed medicines.
Also read: World Sleep Day: Simple ways to sleep better at night
These include:
- Ozempic, a treatment for type 2 diabetes
- Wegovy, a drug used for weight management
According to CBS News, regulators mentioned three patient deaths and additional reports involving suicidal thoughts. The FDA has not concluded that the medication caused these events.
Company response
Novo Nordisk confirmed it received the warning letter and said the matter relates to an inspection conducted on February 7, 2025.
The company stated it has been working to address the issues raised and has submitted multiple updates to the FDA outlining corrective actions. Novo expects the matter to be resolved through continued dialogue with the regulator.
Also read: Study examines link between groundwater and Parkinson’s disease risk
Sources: B.T.
Also read: Can a daily vitamin pill slow aging? New study offers a possible answer